Investor Presentaiton

Building Capability to Deliver Injectable Growth ■ Developing dossiers per our high-entry-barrier APIs to increase value proposition in the supply chain ■ Building a pipeline of complex and difficult to make generic injectable products ■ Significant investment in injectable R&D in the next few years ■ Quality driven, diversified manufacturing operations ■ Promoting our formulations via strategic alliance, especially in China and US ■ Acquiring critical resources via M&A Expected > 15 drug product launched in the next 5 years Introducing 3 to 4 drug products per year in our pipeline 25 25 ScinoPharm

View entire presentation